CARAVAGGIO - Wiki Journal Club CARAVAGGIO enrolled 1,170 patients with cancer-associated VTE, randomizing to either apixaban or dalteparin for 6 months Chief eligibility criteria included symptomatic or incidental VTE, active or recent malignancy, and absence of brain lesions
The CARAVAGGIO findings expand the range of patients with cancer . . . The aim of CARAVAGGIO—the largest study to evaluate the treatment of VTE in cancer—was to assess whether the direct oral anticoagulant apixaban is noninferior to subcutaneous dalteparin for preventing a recurrent VTE in patients with cancer and to evaluate the risk of bleeding
Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing . . . In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to findings from the phase III CARAVAGGIO trial
Researcher View | NCT03045406 - ClinicalTrials. gov Contact information is displayed when a study is open for participants to join Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study